Fraz Muhammad A, Kim B Michelle, Chen John J, Lum Flora, Chen Jinbo, Liu Grant T, Hamedani Ali G
Departments of Neurology and Ophthalmology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Mayo Clinic School of Medicine, Rochester, Minnesota.
Ophthalmology. 2025 Apr;132(4):476-483. doi: 10.1016/j.ophtha.2024.10.031. Epub 2024 Nov 6.
To determine the nationwide prevalence and geographic distribution of idiopathic intracranial hypertension (IIH) among women in the United States.
Retrospective cross-sectional study using Medicaid claims and electronic health record data from the IRIS® Registry (Intelligent Research in Sight) and Sight Outcomes Research Collaborative (SOURCE).
Female Medicaid beneficiaries 18 to 55 years of age with IIH diagnoses and prescriptions for acetazolamide or methazolamide in 2018 were identified, excluding those with other causes of intracranial hypertension. We calculated the proportion of women with IIH in the United States who were insured by Medicaid by combining analyses from the IRIS Registry and SOURCE.
To calculate the number of women with IIH in each state, we divided the number of Medicaid beneficiaries by the proportion of patients insured by Medicaid. We used census data from the 2018 American Community Survey to calculate prevalence.
We examined geographic variation in IIH prevalence using Moran's I statistic and compared it to obesity prevalence data from the 2018 Behavioral Risk Factor Surveillance System. In a validation study, we compared the calculated prevalence of IIH in Minnesota with similar data from the Rochester Epidemiology Project.
Of 13 959 female Medicaid beneficiaries with IIH, 6828 had a prescription for acetazolamide or methazolamide. In the IRIS Registry and SOURCE, 25% of women with IIH were insured by Medicaid (95% confidence interval [CI], 16%-33%), suggesting that 27 312 women 18 to 55 years of age with IIH were taking acetazolamide or methazolamide in 2018 (6828 / 0.25 = 27 312). Prevalence was 3.44 per 10 000 women (95% CI, 2.61-5.39 per 10 000 women), and significant geographic variation was found (Moran I statistic, 0.20; P = 0.03), with higher prevalence in states where obesity was more common. The calculated prevalence of IIH in Minnesota was statistically equivalent to that identified using Rochester Epidemiology Project data (P < 0.05 for equivalence test).
Idiopathic intracranial hypertension affects 3.44 per 10 000 women 18 to 55 years of age in the United States with significant geographic variation, some of which is explained by variation in obesity prevalence.
FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
确定美国女性特发性颅内高压(IIH)的全国患病率及地理分布情况。
采用回顾性横断面研究,利用医疗补助计划索赔数据以及来自IRIS®注册库(智能视觉研究)和视觉结果研究协作组(SOURCE)的电子健康记录数据。
确定了2018年年龄在18至55岁之间、诊断为IIH且开具乙酰唑胺或甲醋唑胺处方的女性医疗补助计划受益人群,排除患有其他颅内高压病因的患者。通过合并IRIS注册库和SOURCE的分析结果,我们计算了参加医疗补助计划的美国IIH女性所占比例。
为计算每个州IIH女性的数量,我们用医疗补助计划受益人数除以参加医疗补助计划的患者比例。我们使用2018年美国社区调查的人口普查数据来计算患病率。
我们使用莫兰指数统计量研究IIH患病率的地理差异,并将其与2018年行为危险因素监测系统的肥胖患病率数据进行比较。在一项验证研究中,我们将明尼苏达州计算出的IIH患病率与罗切斯特流行病学项目的类似数据进行了比较。
在13959名患有IIH的女性医疗补助计划受益人中,6828人开具了乙酰唑胺或甲醋唑胺的处方。在IRIS注册库和SOURCE中,25%的IIH女性参加了医疗补助计划(95%置信区间[CI],16% - 33%),这表明2018年有27312名年龄在18至55岁之间的IIH女性正在服用乙酰唑胺或甲醋唑胺(6828 / 0.25 = 27312)。患病率为每10000名女性中有3.44例(95% CI,每10000名女性中有2.61 - 5.39例),并且发现存在显著的地理差异(莫兰指数统计量,0.20;P = 0.03),在肥胖更为普遍的州患病率更高。明尼苏达州计算出的IIH患病率与使用罗切斯特流行病学项目数据确定的患病率在统计学上相当(等效性检验P < 0.05)。
在美国,特发性颅内高压影响每10000名18至55岁女性中的3.44人,存在显著的地理差异,其中部分差异可由肥胖患病率的差异来解释。
本文末尾的脚注和披露中可能会有专有或商业披露信息。